LogicBio Therapeutics, Inc. Common Stock

LOGC

시가총액 US$6823만

상장 폐지됨

LOGC은(는) 2022년 11월 15일에 상장 폐지됐어요.

소개: LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.